The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma or transformed mycosis fungoides: The REDIRECT study design and rationale.
 
Cassandra Choe-Juliak
Employment - Affimed Therapeutics
Leadership - Affimed Therapeutics
Stock and Other Ownership Interests - Affimed Therapeutics
Travel, Accommodations, Expenses - Affimed Therapeutics; Affimed Therapeutics
 
Karenza M. Alexis
No Relationships to Disclose
 
Sylvia Schwarz
Employment - Affimed Therapeutics
Stock and Other Ownership Interests - Affimed Therapeutics
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Linta Garcia
No Relationships to Disclose
 
Ahmed Sawas
Consulting or Advisory Role - Kirin Pharmaceuticals; Pharmacyclics
Speakers' Bureau - Daiichi Sankyo; Gilead Sciences; Seagen
Research Funding - Affimed Therapeutics (Inst); Astellas Pharma (Inst); Trillium Therapeutics (Inst); Viracta Therapeutics (Inst)